This Hemostasis Diagnostic Devices and Equipment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The hemostasis diagnostic devices and equipment market size has grown rapidly in recent years. It will grow from $5.29 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to clinical diagnostics, surgical procedures, anticoagulant therapy monitoring, hemophilia and bleeding disorders.
The hemostasis diagnostic devices and equipment market size is expected to see rapid growth in the next few years. It will grow to $10.36 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to aging population, cardiovascular and chronic diseases, personalized medicine, rising surgical procedures. Major trends in the forecast period include point-of-care testing, automation and robotics, biomarker discovery, telemedicine and remote monitoring.
The increasing likelihood of older individuals being diagnosed with diseases is fueling the demand for surgeries in the treatment of cardiovascular diseases (CVD) with the use of hemostasis devices. As the elderly population faces a higher risk of disease, there is a growing number of surgical procedures for elderly patients. Hemostasis devices play a vital role in expediting the natural blood clotting process and monitoring anticoagulation, thereby enhancing surgical outcomes and patient comfort. The American Heart Association reports that Americans aged over 80 have a significantly elevated risk of developing cardiovascular disease (CVD), with around 83% of men and 87.1% of women expected to suffer from some form of CVD. Consequently, the widespread implementation of hemostasis devices aims to improve both patient comfort and surgical success rates.
The increasing number of surgical procedures is a driving force behind the growth of the hemostasis diagnostic devices and equipment market. Surgical procedures involve medical interventions that often require incisions or invasive techniques to access and treat various areas of the body. The utilization of hemostasis diagnostic devices in surgical procedures significantly enhances the management of blood clotting, reduces risks, and improves overall surgical efficiency, leading to better patient outcomes. For example, in October 2023, there was an 8.4% increase in cataract surgical procedures in the Czech Republic, totaling 142,670 procedures in 2022 compared to 131,612 in 2021, as reported by the Organization for Economic Co-operation and Development. This surge in surgical procedures is a key driver of growth in the hemostasis diagnostic devices and equipment market.
The emergence of new and enhanced technology in the hemostasis diagnostic device and equipment market is also contributing to its growth. Innovative technologies such as collagen vascular hemostasis devices have been introduced to improve the quality and success rates of surgeries. Collagen, a primary structural protein found in skin and connective tissues, is now being used in the hemostasis diagnostic devices market. For patients undergoing femoral surgery, collagen-based closure devices have been implemented to address potential immobility issues. Research from the American Journal of Neuroradiology, which examined 698 Angio-Seal closures, revealed that the use of Angio-Seal, a collagen hemostasis device, reduced the average time to mobilization by nearly 15 minutes without major complications. This technology is proving to be beneficial in expediting the hemostasis process and enhancing patient mobilization.
In hemostasis diagnostic devices and equipment market, major companies are focusing on the development of innovative products such as automated hemostasis equipment. Automated hemostasis analyzers are specialized medical devices designed to streamline and simplify the assessment of a patient's blood coagulation and clotting abilities. These analyzers leverage advanced technology to perform a series of tests automatically, eliminating the need for manual intervention. For instance, in July 2022, HORIBA Medical launched the Yumizen G800 and G1550 hemostasis analyzers, designed for clinical laboratories with mid- to high workloads. These analyzers offer advanced features, including comprehensive testing capabilities, independent and integrated measurement channels, liquid reagents for various tests, and more. They facilitate continuous sample processing, pre-calibrated tests for ease of use, automated reflex and additional tests, and dedicated STAT sample positions for urgent cases.
In March 2023, Werfen, S.A., a Europe-based company specializing in diagnostic instruments and reagents for hospitals and laboratories, acquired Immucor, Inc. for an undisclosed amount. This acquisition allows Werfen, S.A. to enhance its diagnostic solutions and improve patient care. Immucor, Inc., a US-based company, is known for manufacturing diagnostic products and systems primarily for blood transfusion and immunohematology.
Hemostasis diagnostic devices and equipment are specialized tools used to assess the blood clotting process and diagnose bleeding disorders. These devices enable healthcare professionals to monitor and evaluate different stages of hemostasis, including clot formation, stabilization, and dissolution. They play a crucial role in diagnosing conditions such as hemophilia, vitamin K deficiencies, and other clotting disorders, ensuring effective treatment and management.
The primary product categories within hemostasis diagnostic devices and equipment consist of analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits. Hemostasis diagnostic analyzers are specifically designed tools used to forecast the causes of bleeding during surgery by detecting any underlying hemostatic abnormalities. These diagnostic devices and equipment come in various formats, including automated, semi-automated, and manual options, and they are commonly employed in hospitals, clinics, independent diagnostic laboratories, and other medical settings.
The hemostasis diagnostic devices and equipment market research report is one of a series of new reports that provides hemostasis diagnostic devices and equipment market statistics, including hemostasis diagnostic devices and equipment industry global market size, regional shares, competitors with a hemostasis diagnostic devices and equipment market share, detailed hemostasis diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis diagnostic devices and equipment industry. These hemostasis diagnostic devices and equipment market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the hemostasis diagnostic devices and equipment market include C. R. Bard Inc., Baxter International Inc., Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Company, Chrono-Log Corporation, CSL Behring LLC, F. Hoffmann-La Roche Ltd., Grifols S.A., HemCon Medical Technologies Inc., Integra Life Sciences Corporation, Medtronic PLC, Siemens AG, Thermo Fisher Scientific Inc., Trinity Biotech plc., Ethicon Inc., Boston Scientific Corporation, Olympus Corporation, Cook Group Inc., Halyard Health, Medline Industries Inc., ConMed Corporation, Moog Inc., Argon Medical Devices Inc., B. Braun Interventional Systems Inc., Bio-Rad Laboratories Inc., CareFusion Corporation, Danaher Corporation, DemeTECH Corporation, Diagnostica Stago SAS, Dolphin Sutures, EndoEvolution LLC, Haemonetics Corporation, Internacional Farmacéutica S.A. de C.V., Merit Medical Systems Inc., Quidelortho Corp, STAGO, Stryker Corporation.
North America was the largest region in the global hemostasis diagnostic devices and equipment market in 2024. Asia-Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market. The regions covered in the hemostasis diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hemostasis diagnostic devices and equipment market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Hemostasis diagnostic devices and equipment consist of sales of instruments such as analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits that are used in hemostasis diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hemostasis diagnostic devices and equipment market size has grown rapidly in recent years. It will grow from $5.29 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to clinical diagnostics, surgical procedures, anticoagulant therapy monitoring, hemophilia and bleeding disorders.
The hemostasis diagnostic devices and equipment market size is expected to see rapid growth in the next few years. It will grow to $10.36 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to aging population, cardiovascular and chronic diseases, personalized medicine, rising surgical procedures. Major trends in the forecast period include point-of-care testing, automation and robotics, biomarker discovery, telemedicine and remote monitoring.
The increasing likelihood of older individuals being diagnosed with diseases is fueling the demand for surgeries in the treatment of cardiovascular diseases (CVD) with the use of hemostasis devices. As the elderly population faces a higher risk of disease, there is a growing number of surgical procedures for elderly patients. Hemostasis devices play a vital role in expediting the natural blood clotting process and monitoring anticoagulation, thereby enhancing surgical outcomes and patient comfort. The American Heart Association reports that Americans aged over 80 have a significantly elevated risk of developing cardiovascular disease (CVD), with around 83% of men and 87.1% of women expected to suffer from some form of CVD. Consequently, the widespread implementation of hemostasis devices aims to improve both patient comfort and surgical success rates.
The increasing number of surgical procedures is a driving force behind the growth of the hemostasis diagnostic devices and equipment market. Surgical procedures involve medical interventions that often require incisions or invasive techniques to access and treat various areas of the body. The utilization of hemostasis diagnostic devices in surgical procedures significantly enhances the management of blood clotting, reduces risks, and improves overall surgical efficiency, leading to better patient outcomes. For example, in October 2023, there was an 8.4% increase in cataract surgical procedures in the Czech Republic, totaling 142,670 procedures in 2022 compared to 131,612 in 2021, as reported by the Organization for Economic Co-operation and Development. This surge in surgical procedures is a key driver of growth in the hemostasis diagnostic devices and equipment market.
The emergence of new and enhanced technology in the hemostasis diagnostic device and equipment market is also contributing to its growth. Innovative technologies such as collagen vascular hemostasis devices have been introduced to improve the quality and success rates of surgeries. Collagen, a primary structural protein found in skin and connective tissues, is now being used in the hemostasis diagnostic devices market. For patients undergoing femoral surgery, collagen-based closure devices have been implemented to address potential immobility issues. Research from the American Journal of Neuroradiology, which examined 698 Angio-Seal closures, revealed that the use of Angio-Seal, a collagen hemostasis device, reduced the average time to mobilization by nearly 15 minutes without major complications. This technology is proving to be beneficial in expediting the hemostasis process and enhancing patient mobilization.
In hemostasis diagnostic devices and equipment market, major companies are focusing on the development of innovative products such as automated hemostasis equipment. Automated hemostasis analyzers are specialized medical devices designed to streamline and simplify the assessment of a patient's blood coagulation and clotting abilities. These analyzers leverage advanced technology to perform a series of tests automatically, eliminating the need for manual intervention. For instance, in July 2022, HORIBA Medical launched the Yumizen G800 and G1550 hemostasis analyzers, designed for clinical laboratories with mid- to high workloads. These analyzers offer advanced features, including comprehensive testing capabilities, independent and integrated measurement channels, liquid reagents for various tests, and more. They facilitate continuous sample processing, pre-calibrated tests for ease of use, automated reflex and additional tests, and dedicated STAT sample positions for urgent cases.
In March 2023, Werfen, S.A., a Europe-based company specializing in diagnostic instruments and reagents for hospitals and laboratories, acquired Immucor, Inc. for an undisclosed amount. This acquisition allows Werfen, S.A. to enhance its diagnostic solutions and improve patient care. Immucor, Inc., a US-based company, is known for manufacturing diagnostic products and systems primarily for blood transfusion and immunohematology.
Hemostasis diagnostic devices and equipment are specialized tools used to assess the blood clotting process and diagnose bleeding disorders. These devices enable healthcare professionals to monitor and evaluate different stages of hemostasis, including clot formation, stabilization, and dissolution. They play a crucial role in diagnosing conditions such as hemophilia, vitamin K deficiencies, and other clotting disorders, ensuring effective treatment and management.
The primary product categories within hemostasis diagnostic devices and equipment consist of analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits. Hemostasis diagnostic analyzers are specifically designed tools used to forecast the causes of bleeding during surgery by detecting any underlying hemostatic abnormalities. These diagnostic devices and equipment come in various formats, including automated, semi-automated, and manual options, and they are commonly employed in hospitals, clinics, independent diagnostic laboratories, and other medical settings.
The hemostasis diagnostic devices and equipment market research report is one of a series of new reports that provides hemostasis diagnostic devices and equipment market statistics, including hemostasis diagnostic devices and equipment industry global market size, regional shares, competitors with a hemostasis diagnostic devices and equipment market share, detailed hemostasis diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis diagnostic devices and equipment industry. These hemostasis diagnostic devices and equipment market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the hemostasis diagnostic devices and equipment market include C. R. Bard Inc., Baxter International Inc., Pfizer Inc., Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Company, Chrono-Log Corporation, CSL Behring LLC, F. Hoffmann-La Roche Ltd., Grifols S.A., HemCon Medical Technologies Inc., Integra Life Sciences Corporation, Medtronic PLC, Siemens AG, Thermo Fisher Scientific Inc., Trinity Biotech plc., Ethicon Inc., Boston Scientific Corporation, Olympus Corporation, Cook Group Inc., Halyard Health, Medline Industries Inc., ConMed Corporation, Moog Inc., Argon Medical Devices Inc., B. Braun Interventional Systems Inc., Bio-Rad Laboratories Inc., CareFusion Corporation, Danaher Corporation, DemeTECH Corporation, Diagnostica Stago SAS, Dolphin Sutures, EndoEvolution LLC, Haemonetics Corporation, Internacional Farmacéutica S.A. de C.V., Merit Medical Systems Inc., Quidelortho Corp, STAGO, Stryker Corporation.
North America was the largest region in the global hemostasis diagnostic devices and equipment market in 2024. Asia-Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market. The regions covered in the hemostasis diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hemostasis diagnostic devices and equipment market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Hemostasis diagnostic devices and equipment consist of sales of instruments such as analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits that are used in hemostasis diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Executive Summary
Hemostasis Diagnostic Devices and Equipment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hemostasis diagnostic devices and equipment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hemostasis diagnostic devices and equipment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hemostasis diagnostic devices and equipment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Analyzers; Coagulation Instrument; Other Hemostasis Instruments; Reagents and Kits2) By Device Technology: Automated; Semi-Automated; Manual
3) By End User: Hospitals; Clinics; Independent Diagnostic; Laboratories; Other End Users
Subsegments:
1) By Analyzers: Hematology Analyzers; Platelet Function Analyzers; Thromboelastography (TEG) Analyzers2) By Coagulation Instruments: Prothrombin Time (PT) Instruments; Activated Partial Thromboplastin Time (aPTT) Instruments; Fibrinogen Testing Instruments; Thrombin Time (TT) Instruments
3) By Other Hemostasis Instruments: Blood Clotting Time (BCT) Instruments; Bleeding Time (BT) Test Devices; Hemostatic Forceps and Clips
4) By Reagents and Kits: Coagulation Reagents; Blood Collection Kits; Point-of-care Testing Kits; Thrombosis Kits
Key Companies Mentioned: C. R. Bard Inc.; Baxter International Inc.; Pfizer Inc.; Johnson & Johnson; Abbott Laboratories
Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Hemostasis Diagnostic Devices and Equipment market report include:- C. R. Bard Inc.
- Baxter International Inc.
- Pfizer Inc.
- Johnson & Johnson
- Abbott Laboratories
- Beckman Coulter Inc.
- Becton Dickinson and Company
- Chrono-Log Corporation
- CSL Behring LLC
- F. Hoffmann-La Roche Ltd.
- Grifols S.A.
- HemCon Medical Technologies Inc.
- Integra Life Sciences Corporation
- Medtronic plc
- Siemens AG
- Thermo Fisher Scientific Inc.
- Trinity Biotech plc.
- Ethicon Inc.
- Boston Scientific Corporation
- Olympus Corporation
- Cook Group Inc.
- Halyard Health
- Medline Industries Inc.
- ConMed Corporation
- Moog Inc.
- Argon Medical Devices Inc.
- B. Braun Interventional Systems Inc.
- Bio-Rad Laboratories Inc.
- CareFusion Corporation
- Danaher Corporation
- DemeTECH Corporation
- Diagnostica Stago SAS
- Dolphin Sutures
- EndoEvolution LLC
- Haemonetics Corporation
- Internacional Farmacéutica S.A. de C.V.
- Merit Medical Systems Inc.
- Quidelortho Corp
- STAGO
- Stryker Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 6.18 Billion |
| Forecasted Market Value ( USD | $ 10.36 Billion |
| Compound Annual Growth Rate | 13.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 40 |
